EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial-Reference-Cited by-同舟云学术

EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial

Published:2014-08-12 Issue:6 Volume:111 Page:1065-1071
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Cheng H,Ballman K,Vassilakopoulou M,Dueck A C,Reinholz M M,Tenner K,Gralow J,Hudis C,Davidson N E,Fountzilas G,McCullough A E,Chen B,Psyrri A,Rimm D L,Perez E A

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2014442.pdf

Reference24 articles.

1. Anagnostou VK, Welsh AW, Giltnane JM, Siddiqui S, Liceaga C, Gustavson M, Syrigos KN, Reiter JL, Rimm DL (2010) Analytic variability in immunohistochemistry biomarker studies. Cancer Epidemiol Biomarkers Prev 19 (4): 982–991.

2. Baselga J, Gelmon KA, Verma S, Wardley A, Conte P, Miles D, Bianchi G, Cortes J, McNally VA, Ross GA, Fumoleau P, Gianni L (2010) Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 28 (7): 1138–1144.

3. Bhargava R, Gerald WL, Li AR, Pan Q, Lal P, Ladanyi M, Chen B (2005) EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod Pathol 18 (8): 1027–1033.

4. Camp RL, Chung GG, Rimm DL (2002) Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 8 (11): 1323–1327.

5. Dimou A, Agarwal S, Anagnostou V, Viray H, Christensen S, Gould Rothberg B, Zolota V, Syrigos K, Rimm DL (2011) Standardization of epidermal growth factor receptor (EGFR) measurement by quantitative immunofluorescence and impact on antibody-based mutation detection in non-small cell lung cancer. Am J Pathol 179 (2): 580–589.

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. AXL – a new player in resistance to HER2 blockade;Cancer Treatment Reviews;2023-12

2. In Vivo Biorthogonal Antibody Click for Dual Targeting and Augmented Efficacy in Cancer Treatment;2023-09-07

3. Identification of genetic and immune signatures for the recurrence of HER2-positive breast cancer after trastuzumab-based treatment;Breast Cancer Research and Treatment;2023-04-21

4. Using quantitative single molecule localization microscopy to optimize multivalent HER2-targeting ligands;Frontiers in Medicine;2023-04-17

5. Targeting ERBB2 overcomes resistance to the anti-EGFR therapeutic antibody cetuximab;Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies;2023